Ready to join a team committed to moving gene therapies into the clinical setting for patients and families devastated by rare neurological genetic diseases? AveXis is advancing cutting-edge science to treat rare and life-threatening genetic diseases starting with our clinical-stage, proprietary gene therapy candidate, AVXS-101. We are at the beginning of an incredible journey, and are looking for passionate individuals to join us on this important mission.
AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.
The Director, National Accounts, (DNA), will identify and develop working relationships with key decision makers in the operations and management of formulary coverage and design at targeted National and Regional plans within assigned geography. This includes Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs), State Medicaid, Hospital / Institutions, Integrated Delivery Networks (IDNs), Federal Accounts, Accountable Care Organizations (ACOs) and other emerging markets, as appropriate. The DNA will place themselves in a position to influence the decision-making process at all levels, including Directors of Pharmacy, Medical, Clinical, Policy, and C-Suite executives. This position will maintain account development and management to attain key objectives for the current and future AveXis gene therapy products. The DNA will be responsible for implementing short and long-term business initiatives to ensure appropriate coverage, coding, and reimbursement within the specific managed market segments. Cross-functional leadership and collaboration with both internal and external stakeholders is essential in the Director, National Accounts, (DNA) role.
The Director, National Accounts position is field based with candidate preferably residing within the assigned geography.
The level of this position will be based on the final candidate’s qualifications.
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
AveXis is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity, national origin, genetics, disability, age, sexual orientation or veteran status.